NASDAQ:DWTX
Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. reported net income of −$34.3M in fiscal 2025. The diluted share count rose 384.3%.Summary generated from Dogwood Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 18, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−105.8%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+384.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −16 | −12 | −5 | −12 | −28 |
| Net income | −16 | −12 | −5 | −12 | −34 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KAmendment to articles or bylaws
Jun 17, 2026 - 4Insider transaction report
Jun 17, 2026 - 4Insider transaction report
Jun 17, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026 - 8-KResults of operations and financial condition
May 14, 2026 - DEF 14AProxy statement
Apr 27, 2026